中信建投证券股份有限公司 关于广东永顺生物制药股份有限公司 向不特定合格投资者公开发行股票之保荐工作总结报告书 中信建投证券股份有限公司（以下简称"中信建投证券"、"保荐机构"或"本 机构"）作为广东永顺生物制药股份有限公司（以下简称"永顺生物"、"发行人" 或"公司"）向不特定合格投资者公开发行股票的保荐机构，履行持续督导职责 期间截至 2023 年 12 月 31 日。目前，永顺生物向不特定合格投资者的持续督导 期限已经届满，中信建投证券根据《证券发行上市保荐业务管理办法》《北京证 券交易所股票上市规则（试行）》《北京证券交易所证券发行上市保荐业务管理细 则》等相关法规及规范性文件的要求，出具本持续督导保荐总结报告书。 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、本机构及本人自愿接受中国证监会对保荐总结报告书相关事项进行的任 何质询和调查。 3、本机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理办 法》的有关规定采取的监管措施。 | 保荐机构名称 | 中信建 ...

Recognition and Awards - In 2023, the company was recognized as a specialized and innovative small and medium-sized enterprise in Guangdong Province[5]. - The company's key product, the pig pseudorabies live vaccine, was recognized as the annual influential pseudorabies vaccine in the 2023 China Agricultural and Animal Husbandry Awards[6]. - The company’s "Duck Plague Live Vaccine" was selected as a high-quality and high-tech product in Guangdong Province for 2022[5]. - The company’s "Bacterial Disease Vaccine for Flatfish" won the first prize in the Excellent Achievement Award for Scientific Research in Higher Education in June 2023[5]. - The company’s key product, the pig fever live vaccine, was awarded as the annual influential pig fever vaccine in February 2023[5]. Financial Performance - The company's operating revenue for 2023 was CNY 314,282,861.48, a decrease of 9.87% compared to CNY 348,717,555.84 in 2022[27]. - The net profit attributable to shareholders for 2023 was CNY 58,058,744.25, down 32.59% from CNY 86,122,768.23 in 2022[27]. - The gross profit margin for 2023 was 58.82%, a decline from 62.53% in 2022[27]. - Total assets at the end of 2023 amounted to CNY 787,859,964.71, representing a decrease of 9.33% from CNY 868,923,105.70 at the end of 2022[29]. - The total liabilities decreased by 30.94% to CNY 119,309,799.39 in 2023 from CNY 172,771,172.59 in 2022[29]. - The weighted average return on equity (ROE) based on net profit attributable to shareholders was 8.61% in 2023, down from 12.39% in 2022[27]. - The basic earnings per share for 2023 was CNY 0.21, a decrease of 34.38% compared to CNY 0.32 in 2022[27]. - The net cash flow from operating activities for 2023 was CNY 31,061,874.03, a decline of 55.05% from CNY 69,106,539.37 in 2022[29]. Research and Development - The company invested a total of 25.68 million in R&D during the reporting period, supporting the successful development of 2 new veterinary drug registration certificates and 5 clinical trial approvals[47]. - The company obtained 5 authorized invention patents during the reporting period, enhancing its innovation capabilities[47]. - The company has developed a new cell culture production technology for animal vaccines, which has been patented, and is the first in the country to use this technology for producing a new type of swine fever live vaccine[40]. - The company is actively participating in industry alliances through its subsidiary, which is focused on veterinary biological products[87]. - The company is conducting clinical trials for a new multi-valent inactivated vaccine for poultry, which aims to improve immune protection efficiency and product practicality[100]. Product Development and Innovation - The company is developing a new inactivated vaccine for grass carp vibriosis, completing the production process and clinical trials, which will enhance its aquaculture vaccine portfolio[96]. - The company is advancing the development of a heat-resistant live vaccine for pseudorabies, which aims to improve production technology and increase vaccine capacity while reducing transportation costs[96]. - The company is working on a new inactivated vaccine for porcine epidemic diarrhea, targeting prevalent strains with strong immunogenicity and safety[98]. - The company is developing a new inactivated vaccine for swine encephalitis, which promises higher safety and better immunogenicity compared to existing vaccines[98]. - The company has initiated the production of a new four-valent coccidiosis vaccine, enhancing its product line for poultry diseases[98]. Market Performance - The company’s poultry vaccine sales revenue reached 35.66 million yuan, an increase of 57.96% year-on-year, reflecting successful market strategies[51]. - Export sales revenue amounted to 15.52 million yuan, a growth of 53.83% compared to the previous year, with significant sales in Vietnam and Egypt[51]. - Revenue from the overseas market grew by 53.83%, attributed to an increase in registered products and sales volume[75]. - The gross margin for the pig live vaccine segment was 79.68%, a decrease of 0.59 percentage points compared to the previous year, with revenue declining by 16.97%[72]. - Revenue from other vaccines increased by 39.90%, driven by strong sales of the pig circovirus type 2 inactivated vaccine, which rose from 2.2395 million yuan to 4.9112 million yuan, a growth of 119.30%[75]. Corporate Governance and Management - The company has undergone a change in its board of directors and senior management, with a total of 6 board members and 3 supervisors as of December 28, 2023[172]. - The company has a diverse management team with expertise in finance, veterinary science, and agricultural research, enhancing its strategic decision-making capabilities[176]. - The company has established various committees to ensure effective governance and oversight of management decisions[190]. - The company is focused on expanding its research and development capabilities, particularly in the field of veterinary vaccines and animal health[174]. - The company has a commitment to maintaining transparency and compliance with regulatory requirements during the transition of its board and management[172]. Shareholder Information - The total number of shares at the end of the period is 273,350,000, with 29.36% being unrestricted shares and 70.64% being restricted shares[146]. - The largest shareholder, Guangdong Modern Agricultural Group, holds 106,780,769 shares, representing 39.0638% of the total shares[148]. - The second-largest shareholder, Guangdong Agricultural Science Asset Management Co., holds 53,872,000 shares, accounting for 19.7081%[148]. - The third-largest shareholder, Guangdong Academy of Agricultural Sciences Animal Health Research Institute, owns 30,799,999 shares, which is 11.2676%[148]. - The total number of shareholders holding common stock is 4,267[146]. Corporate Social Responsibility - The company donated RMB 100,000 to the South China Agricultural University Education Development Foundation during the reporting period, emphasizing its commitment to corporate social responsibility[115]. - The company paid approximately RMB 26.23 million in various taxes to the national and local governments during the reporting period, contributing positively to the economy[115]. - The company has implemented a wastewater treatment system with a processing capacity of 500m³/d, ensuring compliance with national environmental regulations[116]. Future Outlook and Strategy - The company aims to solidify its leading position in the pig vaccine segment while enhancing the development of surrounding products, including multi-valent vaccines[122]. - The company plans to reduce production costs of poultry vaccines through process upgrades and to develop new genetically engineered vaccines[122]. - The company is committed to continuous innovation and product upgrades, particularly in the pig vaccine sector, while also increasing the supply of mid- to low-end vaccines[124]. - The company is focusing on building a high-quality talent team through improved assessment mechanisms and innovative incentive methods[125]. - The company is seeking comprehensive credit limits from multiple banks, including China Merchants Bank and Agricultural Bank of China, to support its financial operations[200].

Financial Performance - Operating revenue for the first quarter of 2024 was CNY 66,495,478.87, representing a decrease of 18.00% year-on-year[9] - Net profit attributable to shareholders for the first quarter of 2024 was CNY 8,374,511.51, down 59.92% from the same period last year[9] - Total operating revenue for Q1 2024 was CNY 66,495,478.87, a decrease of 17.9% compared to CNY 81,091,529.35 in Q1 2023[34] - Net profit for Q1 2024 was CNY 8,374,511.51, a decline of 60.0% from CNY 20,894,809.49 in Q1 2023[35] - Total profit for Q1 2024 was CNY 9,420,501.30, a decrease of 60.5% from CNY 23,804,973.70 in Q1 2023[35] - Earnings per share for Q1 2024 was CNY 0.03, compared to CNY 0.08 in Q1 2023[36] - Operating profit for Q1 2024 was CNY 9,360,944.99, down 50.5% from CNY 18,870,406.93 in Q1 2023[35] Cash Flow - The net cash flow from operating activities increased by 214.57% to CNY 16,510,126.57 compared to the previous year[9] - The cash inflow from operating activities for Q1 2024 was CNY 67,850,571.06, an increase of 9.7% compared to CNY 61,928,602.02 in Q1 2023[39] - The net cash flow from operating activities for Q1 2024 was CNY 16,510,126.57, a significant recovery from a negative CNY 14,410,166.78 in Q1 2023[39] - The cash inflow from investment activities in Q1 2024 was CNY 46,599,181.42, while the cash outflow was CNY 31,004,727.00, resulting in a net cash flow of CNY 15,594,454.42[40] - The cash inflow from financing activities for Q1 2024 was CNY 12,785,666.05, compared to CNY 35,100,000.00 in Q1 2023, indicating a decrease of 63.5%[40] - The net increase in cash and cash equivalents for Q1 2024 was CNY 44,629,965.73, contrasting with a decrease of CNY 36,683,350.52 in Q1 2023[40] - The total cash outflow for operating activities in Q1 2024 was CNY 51,340,444.49, down from CNY 76,338,768.80 in Q1 2023, reflecting a reduction of 32.8%[39] Assets and Liabilities - Total assets as of March 31, 2024, reached CNY 801,866,008.23, an increase of 1.78% compared to the previous year[9] - The company's asset-liability ratio remained stable at 15.58% for both the parent and consolidated entities[9] - Current liabilities rose to CNY 114,482,878.12, up from CNY 108,233,580.73, indicating an increase of about 3.1%[30] - Short-term borrowings increased significantly to CNY 27,388,015.75 from CNY 19,401,038.96, representing a rise of approximately 41.1%[30] - The total liabilities increased to CNY 124,941,331.40 from CNY 119,309,799.39, reflecting a growth of approximately 4.4%[30] - The company's total equity reached CNY 676,924,676.83, up from CNY 668,550,165.32, marking an increase of about 0.6%[30] - The company's total non-current assets amounted to CNY 219,383,096.16, down from CNY 226,312,983.97, indicating a decrease of about 3.1%[32] Shareholder Information - The total number of shares held by the top ten shareholders is 209,022,215, accounting for 76.47% of the total shares[18] - The largest shareholder, Guangdong Modern Agriculture Group Co., Ltd., holds 39.0638% of the shares, while the second-largest shareholder, Guangdong Agricultural Science Assets Management Co., Ltd., holds 19.7081%[19] - The company has no pledged or judicially frozen shares among its top ten shareholders[20] Other Financial Metrics - The company reported a significant decrease in investment income by 91.34% to CNY 42,234.34 due to changes in investment structure[11] - The gross profit margin declined due to a shift in product sales structure, with a notable increase in the sales proportion of lower-margin products[11] - Research and development expenses for Q1 2024 were CNY 5,350,715.65, a decrease of 19.5% from CNY 6,647,428.05 in Q1 2023[34] - Other income for Q1 2024 was CNY 1,248,740.12, an increase from CNY 1,133,581.43 in Q1 2023[34] - Investment income for Q1 2024 was CNY 1,608,775.65, up from CNY 1,050,083.33 in Q1 2023[34] - The company reported a credit impairment loss of CNY 413,757.44 in Q1 2024, compared to a gain of CNY 894,878.38 in Q1 2023[35]

二、募集资金管理情况 证券代码：839729 证券简称：永顺生物 公告编号：2024-028 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载 、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及 连带法律责任。 一、募集资金基本情况 经中国证券监督管理委员会证监许可〔2020〕1271号文核准，并经全国中 小企业股份转让系统有限责任公司同意，本公司由主承销商中信建投证券股份 有限公司采用向不特定合格投资者公开发行方式发行人民币普通股(A股)股票 1,200,000股，每股面值1元，发行价为每股人民币29.88元，募集资金总额为 35,856,000.00元，扣除发行权益性证券直接相关的新增费用5,170,089.06元后， 募集资金净额为30,685,910.94元，本次发行募集资金用途主要为投资于兽用生 物制品的研制与开发项目。 上述募集资金已由主承销商中信建投证券股份有限公司于2020年7月15日汇 入公司募集资金存放专项账户，募集资金到位情况业经天健会计师事务所(特殊 普通合伙)验证，并由其出具《验资报告》（天健验〔2020〕2-27号）。 为规范公司募集资金的管理 ...

广东永顺生物制药股份有限公司 2023 年度审计报告 天健会计师事务所 Pan-China Certified Public Accountants | | | | 一、审计报告……………………………………………………… 第 | 1—6 页 | | --- | --- | | 二、财务报表……………………………………………………… 第 7—14 | 页 | | （一）合并资产负债表…………………………………………… 第 | 7 页 | | （二）母公司资产负债表………………………………………… 第 | 8 页 | | （三）合并利润表………………………………………………… 第 | 9 页 | | （四）母公司利润表………………………………………………第 | 10 页 | | （五）合并现金流量表……………………………………………第 | 11 页 | | （六）母公司现金流量表…………………………………………第 | 12 页 | | （七）合并所有者权益变动表……………………………………第 | 13 页 | | （八）母公司所有者权益变动表…………………………………第 | 14 页 | | 三、财务报表附注…… ...

为回报公司股东，与股东共享公司经营成果，根据《公司法》和《公司章程》 的相关规定，公司拟以未分配利润对股东进行 2023 年年度权益分派。 一、权益分派预案情况 根据公司 2024 年 4 月 29 日披露的 2023 年年度报告（财务报告已经审计）， 截至 2023 年 12 月 31 日，上市公司合并报表归属于母公司的未分配利润为 136,512,308.27 元，母公司未分配利润为 136,458,026.01 元。 证券代码：839729 证券简称：永顺生物 公告编号：2024-016 广东永顺生物制药股份有限公司 2023 年年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 公司本次权益分派预案如下：公司目前总股本为 273,350,000 股，根据扣除 回购专户 3,600,000 股后的 269,750,000 股为基数，以未分配利润向全体股东每 10 股派发现金红利 1.8 元（含税）。本次权益分派共预计派发现金红利 48,555,000 元。 公司将以权益分派实施时 ...

非经营性资金占用及其他关联资金往来情况的 广东永顺生物制药股份有限公司 目 录 专项审计说明 天健会计师事务所 Pan-China Certified Public Accountants 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 二、非经营性资金占用及其他关联资金往来情况汇总表………………第 3 页 | | 三、附件……………………………………………………………… 第 | 4-7 | 页 | | --- | --- | --- | --- | | (一) | 本所营业执照复印件……………………………………………第 | 4 | 页 | | (二) | 本所执业证书复印件……………………………………………第 | 5 | 页 | | (三) | 签字注册会计师执业证书复印件……………………………第 | 6-7 | 页 | 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健审〔2024〕2-279 号 广东永顺生物制药股份有限公司全体股东： 我们接受委托，审计了广东永顺生物制药股份有限公司（以下简称永顺生物 公司）2023 年度财 ...

广东永顺生物制药股份有限公司 募集资金年度存放与使用情况鉴证报告 募集资金年度存放与使用情况鉴证报告 天健审〔2024〕2-278 号 广东永顺生物制药股份有限公司全体股东： 我们鉴证了后附的广东永顺生物制药股份有限公司（以下简称永顺生物公司） 管理层编制的 2023 年度《关于募集资金年度存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 天健会计师事务所 Pan-China Certified Public Accountants 目 录 一、募集资金年度存放与使用情况鉴证报告………………………第 1—2 页 二、关于募集资金年度存放与使用情况的专项报告 …………… 第 3—7 页 三、附件………………………………………………………… 第 8—11 页 (一) 本所营业执照复印件……………………………………… 第 8 页 (二) 本所执业证书复印件……………………………………… 第 9 页 (三) 签字注册会计师执业证书复印件………………… 第 10—11 页 本鉴证报告仅供永顺生物公司年度报告披露时使用，不得用作任何其他目的。 我们同意将本鉴证报告作为永顺生物公司年度报告的必备文件，随同其他 ...

证券代码：839729 证券简称：永顺生物 公告编号：2024-027 广东永顺生物制药股份有限公司 第五届监事会第二次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 公司监事会编制了《2023 年度监事会工作报告》，对 2023 年度公司的经营 情况和监事会日常工作情况进行回顾。 （一）会议召开情况 1.会议召开时间：2024 年 4 月 26 日 2.会议召开地点：广东省现代农业集团有限公司二楼会议室 3.会议召开方式：现场表决 4.发出监事会会议通知的时间和方式：2024 年 4 月 15 日以书面方式发出 5.会议主持人：监事会主席梅双 6.召开情况合法、合规、合章程性说明： 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 票。 3.回避表决情况 本议案不涉及关联交易事项，无需回避表决。 本议案尚需提交股东大会审议。 本次会议的参与表决监事人数、召集、召开程序和议事内容均符合《公司法》、 《公司章程》及相关法律法规的规定，所作决议合法有效。 （二）会 ...

证券代码：839729 证券简称：永顺生物 公告编号：2024-024 广东永顺生物制药股份有限公司会计政策变更公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、变更概述 （一）变更日期：2023 年 1 月 1 日 （二）变更前后会计政策的介绍 1.变更前采取的会计政策： 本次会计政策变更前，公司执行财政部发布的《企业会计准则——基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他 相关规定。 公司本次会计政策变更事项无需提交股东大会审议。 三、董事会关于本次会计政策变更合理性的说明 公司董事会认为：本次会计政策变更是根据财政部相关政策、规定的要求进 行的变更，符合国家相关法律的要求，不存在损害公司及股东利益的情形，不会 对公司财务状况、经营成果产生重大影响。董事会同意本次会计政策变更事项。 四、监事会对于本次会计政策变更的意见 公司监事会认为：本次会计政策变更是根据财政部发布的《企业会计准则解 释第 16 号》要求进行，符合相关规定。本次会计政策的变更及其决策程 ...